Orphan drugs for rare diseases: Grounds for special status

Drug Development Research

Volumn 73, Issue 3, 2012, Pages 115-119

  Picavet, Eline ^a   Dooms, Marc ^b   Cassiman, David ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

ethics; incremental cost effectiveness ratio; market access; orphan drug; quality adjusted life year; rare disease; societal values; special status

Indexed keywords

ORPHAN DRUG;

BUDGET; CHRONIC DISEASE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EUROPE; HEALTH CARE; HEALTH ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REIMBURSEMENT; REVIEW; UNITED KINGDOM;

EID: 84861100238     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21005     Document Type: Review

References (40)

1. Annemans L, Cleemput I, Simoens S, Arickx F, Hulstaert F, Bogaert M,. 2010. The increasing role of health economic evaluations in drug development. Drug Dev Res 71: 457-462.
2. Barrera LA, Galindo GC,. 2010. Ethical aspects on rare diseases. Adv Exp Med Biol 686: 493-511.
3. Boon W, Moors E,. 2008. Exploring emerging technologies using metaphors - a study of orphan drugs and pharmacogenomics. Soc Sci Med 66: 1915-1927.
4. Burls A, Austin D, Moore D,. 2005. Commissioning for rare diseases: view from the frontline. BMJ 331: 1019-1021. (Pubitemid 41552457)
5. Clarke JT,. 2006. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 174: 189-190. (Pubitemid 43166273)
6. Claxton KP, Sculpher MJ,. 2006. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 24: 1055-1068. (Pubitemid 44683363)
7. Cook JP, Vernon JA, Manning R,. 2008. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 26: 551-556. (Pubitemid 351871550)
8. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S,. 2010. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 13: 295-301.
9. DiMasi JA, Hansen RW, Grabowski HG,. 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185. (Pubitemid 36279392)
10. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S,. 2009. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology. Can J Clin Pharmacol 16: e273-e281.
11. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J,. 2007. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23: 36-42. (Pubitemid 46648298)
12. European Commission. 2000. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official J Eur Communities L18: 1-5.
13. European Commission. 2011. Special Eurobarometer 361 European awareness of rare diseases. Accessedon 13 December 2011;.
14. European Medicines Agency. 2006. Guideline on clinical trials in small populations. Accessed on 12 December 2011;.
15. Eurordis. 2005. Rare diseases: understanding this public health priority. Accessed on 20 December 2011;.
16. Gericke CA, Riesberg A, Busse R,. 2005. Ethical issues in funding orphan drug research and development. J Med Ethics 31: 164-168. (Pubitemid 40378689)
17. Hughes DA, Tunnage B, Yeo ST,. 2005. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98: 829-836. (Pubitemid 41631334)
18. Loth K,. 2011. The cost and price of orphan drugs. Care and cure for rare diseases: social and ethical aspects. Lecture at the King Baudouin Foundation Symposium, Brussels, Belgium, February 22 2011.
19. McCabe C,. 2010. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. Eur J Hosp Pharm Pract 16: 22-24.
20. McCabe C, Stafinski T, Menon D,. 2010. Is it time to revisit orphan drug policies? BMJ 341: 614-615.
21. National Institute for Clinical Excellence. 2004. NICE citizens council report ultra orphan drugs. Accessed on 14 December 2011;.
22. Nord E,. 1993. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 24: 227-238. (Pubitemid 23280732)
23. Orofino J, Soto J, Casado MA, Oyaguez I,. 2010. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 8: 301-315.
24. Orphanet. 2012. Orphanet - the portal for rare diseases and orphan drugs. Accessed on 22 December 2011;.
25. Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J, Reid C,. 2008. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ 11: 235-243.
26. Persad G, Wertheimer A, Emanuel EJ,. 2009. Principles for allocation of scarce medical interventions. Lancet 373: 423-431.
27. Pinxten W, Denier Y, Dooms M, Cassiman JJ, Dierickx K,. 2011. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European orphan drug regulation. J Med Ethics 1-6; doi: 10.1136/medethics-2011-100094.
28. Raftery J,. 2010. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 340: 1282-1288.
29. Regnstrom J, Koenig F, Aronsson B, Reimer T, Svendsen K, Tsigkos S, Flamion B, Eichler HG, Vamvakas S,. 2010. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 66: 39-48.
30. Reidenberg MM,. 2006. Are drugs for rare diseases "essential?" Bull World Health Organ 84: 686.
31. Rinaldi A,. 2005. Adopting an orphan. EMBO Rep 6: 507-510. (Pubitemid 40973956)
32. Schieppati A, Henter JI, Daina E, Aperia A,. 2008. Why rare diseases are an important medical and social issue. Lancet 371: 2039-2041. (Pubitemid 351799861)
33. Simoens S,. 2010a. How to assess the value of medicines? Front Pharmacol 1: 1-9.
34. Simoens S,. 2010b. Orphan drugs and rare diseases: a multifaceted story. Eur J Hosp Pharm Pract 16: 18.
35. Simoens S,. 2011. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 6: 1-8.
36. Tambuyzer E,. 2010. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 9: 921-929.
37. The European Parliament. 2000. Charter of fundamental rights of the European Union. Accessed on 04 January 2012;.
38. Tunis SR, Pearson SD,. 2006. Coverage options for promising technologies: Medicare's "coverage with evidence development." Health Aff 25: 1218-1230. (Pubitemid 44497620)
39. Ubel PA, Loewenstein G,. 1996. Distributing scarce livers: the moral reasoning of the general public. Soc Sci Med 42: 1049-1055. (Pubitemid 26109024)
40. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldie E, Moaven N, Sidransky E, Lee JC,. 2011. Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 286: 28080-28088.